NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Whitehawk Therapeutics, Inc. (WHWK) Stock Analysis

Whitehawk Therapeutics, Inc. (WHWK) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

WHWK

$4.60

−$0.03 (−0.65%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare WHWK with… →

WHWK Key Statistics

As of Sep 4, 2026
Trading
Open
$4.59
Previous Close
$4.63
Day's Range
4.53–4.65
52-Week Range
1.76–5.50
Volume
178.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.81
Valuation
Market Cap
$262.24M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.21
Financials (FY)
Revenue (FY)
$7.15M−72.50%
Net Income (FY)
−$20.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
57.01M
1-Year Return
+154.14%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
457.07K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

WHWK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+90.08%
2025−23.30%
2024+56.19%
2023−84.26%
2022−46.87%
2021+64.29%
2020+57.05%
2019−63.29%
2018 (partial year)−62.22%

As of September 4, 2026.

WHWK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.15M−$20.60M−288.3%
2024$25.98M−$63.69M−245.1%
2023$24.35M−$65.77M−270.0%
2022$15.22M−$60.51M−397.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.15M$6.39M−$114.40M−$20.60M−288.3%
2024$25.98M$22.96M−$64.82M−$63.69M−245.1%
2023$24.35M$21.55M−$71.93M−$65.77M−270.0%
2022$15.22M$13.88M−$58.96M−$60.51M−397.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

WHWK Valuation vs Biotechnology Median

Median of 656 stocks
MetricWHWKBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Whitehawk Therapeutics, Inc. (WHWK) carries a market capitalisation of $262.24M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 32.

The most recent close on file for WHWK is $4.60, dated September 4, 2026. That is −$0.03 (−0.65%) against the previous close. The 52-week range on file runs from $1.76 to $5.50. The latest close sits 161.36% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $7.15M. That is −72.50% against the prior fiscal year, when revenue was $25.98M. The same year closed with a net loss of $20.60M. The reported profit margin is 0%. Trailing earnings per share are −1.21.

Across the 4 fiscal years on file, revenue moves from $15.22M in 2022 to $7.15M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.81. Daily returns over the trailing 8 years annualize to a volatility of 87.39%. Over the trailing twelve months the price has returned +154.14%. Measured over 5 years, that is −30.11% a year compounded.

Growth & Income

No dividend is on file for WHWK.

So far in 2026 the price is +90.08%. Across the complete calendar years on file, 2021 returned +64.29% and 2023 returned −84.26%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Whitehawk Therapeutics, Inc. (WHWK) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Whitehawk Therapeutics, Inc. WHWK $262.24M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Whitehawk Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Visit website →